Gastrin-releasing peptide receptor (GRPR) as a novel biomarker and therapeutic target in prostate cancer
Open Access
- 5 March 2024
- journal article
- review article
- Published by Taylor & Francis in Annals of Medicine
- Vol. 56 (1) , 2320301
Abstract
Aim: This comprehensive review aims to explore the potential applications of Gastrin-releasing peptide receptor (GRPR) in the diagnosis and treatment of prostate cancer. Additionally, the study investigates the role of GRPR in prognostic assessment for individuals afflicted with prostate cancer.Methods: The review encompasses a thorough examination of existing literature and research studies related to the upregulation of GRPR in various tumor types, with a specific focus on prostate. The review also evaluates the utility of GRPR as a molecular target in prostate cancer research, comparing its significance to the well-established Prostate-specific membrane antigen (PSMA). The integration of radionuclide-targeted therapy with GRPR antagonists is explored as an innovative therapeutic approach for individuals with prostate cancer.Results: Research findings suggest that GRPR serves as a promising molecular target for visualizing low-grade prostate cancer. Furthermore, it is demonstrated to complement the detection of lesions that may be negative for PSMA. The integration of radionuclide-targeted therapy with GRPR antagonists presents a novel therapeutic paradigm, offering potential benefits for individuals undergoing treatment for prostate cancer.Conclusions: In conclusion, this review highlights the emerging role of GRPR in prostate cancer diagnosis and treatment. Moreover, the integration of radionuclide-targeted therapy with GRPR antagonists introduces an innovative therapeutic approach that holds promise for improving outcomes in individuals dealing with prostate cancer. The potential prognostic value of GRPR in assessing the disease's progression adds another dimension to its clinical significance in the realm of urology.Keywords
Funding Information
- Key Research and Development Program of Hunan Province of China (2021SK2014)
- National Natural Science Foundation of China (82272907, 81974397)
- the clinical research foundation of the National Clinical Research Center for Geriatric Diseases (2022LNJJ13)
This publication has 97 references indexed in Scilit:
- A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion–Resistant GrowthCancer Research, 2009
- Bombesin Receptor Antagonists May Be Preferable to Agonists for Tumor TargetingJournal of Nuclear Medicine, 2008
- The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancerCancer, 2007
- Variation in the Definition of Biochemical Recurrence in Patients Treated for Localized Prostate Cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel Report and Recommendations for a Standard in the Reporting of Surgical OutcomesJournal of Urology, 2007
- Defining Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Proposal for a Standardized DefinitionJournal of Clinical Oncology, 2006
- Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus ConferenceInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer.2006
- Androgen Deprivation Therapy for Prostate CancerJAMA, 2005
- Gastrin Releasing Peptide-Preferring Bombesin Receptors Mediate Growth of Human Renal Cell CarcinomaJournal of the American Society of Nephrology, 2000
- Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation.1999